| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.2 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | -0.038 | 0.2 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.061 | 0.2 |